Waterloo Wellington Regional Cancer Program

Ontario Health (Cancer Care Ontario)

Final Discharge Recommendations

Colposcopy services

Colposcopist's name:

Contact information:

Patient information:

Date:

This patient is discharged from colposcopy and should resume cervical screening in primary care. See below for information on their colposcopy results and next screening interval in primary care:

Results:

Patient was **not treated** (HSIL or AIS histology not detected) and had the following results:

- □ Entered colposcopy with normal (NILM) or low-grade (ASCUS, LSIL) cytology and no HPV test at discharge (not required)
- □ Entered colposcopy with high-grade cytology (ASC-H, LSIL-H, AGC, HSIL, AEC)* and HPV-negative at discharge
- □ Entered colposcopy with high-grade cytology (ASC-H, LSIL-H, AGC, HSIL, AEC)* and HPV-positive at discharge

Patient was treated for **HSIL histology** and had the following results:

- □ HPV-negative at first post-treatment visit and at discharge
- □ HPV-positive at first post-treatment visit and HPV-negative at discharge
- $\hfill\square$ HPV-negative at first post-treatment visit and HPV-positive at discharge
- □ HPV-positive at first post-treatment visit and at discharge

Patient was treated for AIS histology and HPV-negative at discharge

Your next steps:

Screen patient in 5 years (average risk screening) and manage results according to routine cervical																		
screenin	g re	con	nmenc	lations														
1.			•								、							

Screen patient in **3 years** (immunocompromised screening) and manage results according to routine cervical screening recommendations

Screen patient in **2 years** (moderate risk screening)**

If result is HPV-positive (regardless of HPV type), refer back to colposcopy

Version 1.0 January 2025

For more information, please scan QR code or go to: <u>https://www.grhosp.on.ca/cancerwaterloowellington/colposcopists</u>



• If result is HPV-negative:

□ Return to average risk screening in 5 years or immunocompromised screening in 3 years

- □ Re-screen in **2 years** and if result is:
 - HPV-positive (regardless of HPV type), refer back to colposcopy
 - HPV-negative, return to average risk screening in 5 years or immunocompromised screening in 3 years
- □ Re-screen in **2 years** and if result is:
 - HPV-positive (regardless of HPV type), refer back to colposcopy
 - HPV-negative, re-screen in **2 years** and if result is:
 - HPV-positive (regardless of HPV type), refer back to colposcopy
 - HPV-negative, return to average risk screening in 5 years or immunocompromised screening in 3 years

For more information on the Ontario Cervical Screening Program's post-discharge screening recommendations, visit <u>ontariohealth.ca/OCSP-recommendations</u>.

[Physician Name], MD, Colposcopist

Additional notes:

Available online: <u>ontariohealth.ca/OCSP-colposcopy</u>

For more information, please scan QR code or go to: <u>https://www.grhosp.on.ca/cancerwaterloowellington/colposcopists</u>



^{*} Patients referred to colposcopy with SCC, ACC, ACC-E or PDC cytology results might be referred to a gynecology oncology centre or another provider. Any further follow-up in primary care will be based on that provider's recommendations.

^{**} Patients ages 65 to 69 who are discharged from colposcopy should continue to screen until age 74.

ACC = adenocarcinoma; ACC-E = endocervical adenocarcinoma; AEC = atypical endocervical cells; AGC = atypical glandular cells; AIS = adenocarcinoma in situ; ASC-H = atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; ASCUS = abnormal atypical squamous cells of undetermined significance; HPV = human papillomavirus; HSIL = high-grade squamous intraepithelial lesion; LSIL = low-grade squamous intraepithelial lesion; CSIL = low-grade squamous intraepithelial lesion; CSIL = low-grade squamous intraepithelial lesion; CSIL = low-grade squamous cell carcinoma

Version 1.0

January 2025